According to Vision Research Reports, the global hepatitis therapeutics market size is expected to hit around US$ 25.23 billion by 2027 and is projected to expand at a CAGR of 2.6% from 2020 to 2027.
The global market is anticipated to be driven by a rise in viraemic prevalence, promising pipeline of hepatitis drugs, and supportive government initiatives encouraging patients in the adoption of hepatitis drugs. The hepatitis therapeutics market in Asia Pacific is expected to expand at a high CAGR of 3.0%, due to a high incidence of hepatitis in emerging countries such as India and China and presence of local players providing a wide range of generic hepatitis drugs in the region.
Increase in Prevalence of Viral Hepatitis Drives Market
Hepatitis is a significant public health concern across the globe. According to the World Health Organization (WHO), in 2015, approximately, 257 million people globally, or 3.5% of the population, were living with chronic hepatitis B infections. Rise in the consumption of alcohol, infections from contaminated blood sources, and increase in the number of autoimmune diseases are leading to a rise in the cases of inflammation of the liver. Viral hepatitis is an important source of morbidity and mortality globally. As per WHO estimates, viral hepatitis caused 1.34 million deaths in 2015, a number higher than the deaths caused by HIV. Additionally, mortality associated with viral hepatitis has increased by 22% since 2000, and the number is further expected to increase over the next few years. Hence, these factors are likely to boost demand for hepatitis therapeutics over the forecast period.
Hepatitis C Segment Dominated the Market
In terms of disease type, the global hepatitis therapeutics market has been classified into hepatitis A, hepatitis B, hepatitis C, and others. The hepatitis C segment is projected to account for a leading share of the global market during the forecast period, owing to the high prevalence of hepatitis C in developing and developed regions and availability of effective drug regimens in the market. According to the World Health Organization (WHO), approximately 71 million people were infected with chronic hepatitis C in 2017. Hepatitis C increases the risk of liver cirrhosis and is the leading cause of liver transplant in North America and Europe. Development of advanced therapeutics by leading industry players for the effective management of disease is expected to pave the way for the hepatitis C segment over the coming years. The hepatitis B segment is projected to expand at a rapid pace over the forecast period, owing to a high mortality rate associated with hepatitis B.
Multi-class Combination to be the Most Promising Segment to Invest in
Based on drug class, the global hepatitis therapeutics market has been segmented into NS5A inhibitors, nucleotide analog reverse transcriptase inhibitors, multi-class combination, nucleotide analog NS5B polymerase inhibitors, interferon & ribavirin, and others. The multi-class combination segment is projected to expand at a high CAGR during the forecast period, owing to an increase in viraemic prevalence worldwide. Industry players are focused on developing combinational therapy as it is highly effective and has fewer side-effects compared to a single regimen for the treatment of hepatitis C. Mavyret and Epclusa are some of the combinational therapeutics recently approved by the U.S. FDA.
Asia Pacific Market to Witness Strong Growth and Create High Incremental Opportunity
In terms of region, the global hepatitis therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is anticipated to account for a leading share of the global market during the forecast period, owing to high awareness and access to advanced hepatitis therapeutics and high affordability of patients in the region. The hepatitis therapeutics market in Europe is expected to expand at a substantial rate between 2020 and 2027. The market in Asia Pacific is likely to expand at a rapid pace in the next few years. This is attributed to a growing patient population, increasing penetration of global manufacturers, and rising government initiatives to promote disease awareness in the region. The hepatitis therapeutics market in Latin America and Middle East & Africa is anticipated to expand at a steady pace from 2020 to 2027.
Growth Strategies by Key Market Players
Key players profiled in this report are Merck & Co., Inc., Gilead Sciences, Inc., AbbVie Inc., Bristol Myers Squibb, F. Hoffmann-La Roche, Ltd., LAURUS Labs, Zydus Cadila, Hetero Healthcare Limited, NATCO Pharma Limited, and Cipla, Inc. Companies operating in the global hepatitis therapeutics market focus on R&D to develop innovative drugs used for the effective treatment of hepatitis. Market players also resort to strategic collaborations and license agreements with domestic players to expand their market foothold in developing countries.
The report analyzes and forecasts the hepatitis therapeutics market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2020 to 2027. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.
This report first introduces the background of hepatitis therapeutics, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major hepatitis therapeutics companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of hepatitis therapeutics upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of hepatitis therapeutics and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global hepatitis therapeutics market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the hepatitis therapeutics market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of hepatitis therapeutics market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Hepatitis Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Hepatitis Therapeutics Market Analysis and Forecasts, 2016–2026
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis
5. Market Outlook
5.1.Pipeline Analysis
5.2.New Product Launch, Approvals & Patent Expiry
5.3.Regulatory Scenario
6. Global Hepatitis Therapeutics Market Analysis and Forecasts, by Disease Type
6.1. Introduction & Definition
6.2. Market Value Forecast, by Disease Type, 2016–2026
6.2.1. Hepatitis A
6.2.2. Hepatitis B
6.2.3. Hepatitis C
6.2.4. Others
6.3. Market Attractiveness, by Disease Type
7. Global Hepatitis Therapeutics Market Analysis and Forecasts, by Drug Class
7.1. Introduction & Definition
7.2. Market Value Forecast, by Drug Class, 2016–2026
7.2.1. Nucleotide Analog Reverse Transcriptase Inhibitor
7.2.2. NS5A Inhibitor
7.2.3. Multi Class Combination
7.2.4. Nucleotide Analog NS5B Polymerase Inhibitor
7.2.5. Interferon & Ribavirin
7.2.6. Others
7.3. Market Attractiveness, by Drug Class
8. Global Hepatitis Therapeutics Market Analysis and Forecasts, by Distribution Channel
8.1. Introduction & Definition
8.2. Market Value Forecast, by Distribution Channel, 2016–2026
8.2.1. Hospital Pharmacies
8.2.2. Retail Pharmacies
8.2.3. Online Pharmacies
8.4. Market Attractiveness, by Distribution Channel
9. Global Hepatitis Therapeutics Market Analysis and Forecasts, by Region
9.1. Market Value Forecast, by Region
9.1.1. North America
9.1.2. Europe
9.1.3. Asia Pacific
9.1.4. Latin America
9.1.5. Middle East & Africa
9.2. Market Attractiveness, by Country/Region
10. North America Hepatitis Therapeutics Market Analysis and Forecast
10.1.Introduction
10.2.Market Value Forecast, by Disease Type, 2016–2026
10.2.1. Hepatitis A
10.2.2. Hepatitis B
10.2.3. Hepatitis C
10.2.4. Others
10.3.Market Value Forecast, by Drug Class, 2016–2026
10.3.1. Nucleotide Analog Reverse Transcriptase Inhibitor
10.3.2. NS5A Inhibitor
10.3.3. Multi Class Combination
10.3.4. Nucleotide Analog NS5B Polymerase Inhibitor
10.3.5. Interferon & Ribavirin
10.3.6. Others
10.4.Market Value Forecast, by Distribution Channel, 2016–2026
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5.Market Value Forecast, by Country, 2016–2026
10.5.1. U.S.
10.5.2. Canada
10.6.Market Attractiveness, Analysis
10.6.1.By Disease Type
10.6.2. B Drug Class
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Hepatitis Therapeutics Market Analysis and Forecast
11.1.Introduction
11.2.Market Value Forecast, by Disease, 2016–2026
11.2.1. Hepatitis A
11.2.2. Hepatitis B
11.2.3. Hepatitis C
11.2.4. Others
11.3.Market Value Forecast, by Drug Class, 2016–2026
11.3.1. Nucleotide Analog Reverse Transcriptase Inhibitor
11.3.2. NS5A Inhibitor
11.3.3. Multi-class Combination
11.3.4. Nucleotide Analog NS5B Polymerase Inhibitor
11.3.5. Interferon & Ribavirin
11.3.6. Others
11.4.Market Value Forecast, by Distribution Channel, 2016–2026
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5.Market Value Forecast, by Country, 2016–2026
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6.Market Attractiveness, Analysis
11.6.1. By Disease Type
11.6.2. By Drug Class
11.6.3. By Distribution Channel
11.6.4. By Country
12. Asia Pacific Hepatitis Therapeutics Market Analysis and Forecast
12.1.Introduction
12.2.Market Value Forecast, by Disease Type, 2016–2026
12.2.1. Hepatitis A
12.2.2. Hepatitis B
12.2.3. Hepatitis C
12.2.4. Others
12.3.Market Value Forecast, by Drug Class, 2016–2026
12.3.1. Nucleotide Analog Reverse Transcriptase Inhibitor
12.3.2. NS5A Inhibitor
12.3.3. Multi-class Combination
12.3.4. Nucleotide Analog NS5B Polymerase Inhibitor
12.3.5. Interferon & Ribavirin
12.3.6. Others
12.4.Market Value Forecast, by Distribution Channel, 2016–2026
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5.Market Value Forecast, by Country, 2016–2026
12.5.1. Japan
12.5.2. China
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6.Market Attractiveness, Analysis
12.6.1. By Disease Type
12.6.2. By Drug Class
12.6.3. By Distribution Channel
12.6.4. By Country
13. Latin America Hepatitis Therapeutics Market Analysis and Forecast
13.1.Introduction
13.2.Market Value Forecast, by Disease Type, 2016–2026
13.2.1. Hepatitis A
13.2.2. Hepatitis B
13.2.3. Hepatitis C
13.2.4. Others
13.3.Market Value Forecast, by Drug Class, 2016–2026
13.3.1. Nucleotide Analog Reverse Transcriptase Inhibitor
13.3.2. NS5A Inhibitor
13.3.3. Multi-class Combination
13.3.4. Nucleotide Analog NS5B Polymerase Inhibitor
13.3.5. Interferon & Ribavirin
13.3.6. Others
13.4.Market Value Forecast, by Distribution Channel, 2016–2026
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5.Market Value Forecast, by Country, 2016–2026
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6.Market Attractiveness, Analysis
13.6.1. By Disease Type
13.6.2. By Drug Class
13.6.3. By Distribution Channel
13.6.4. By Country
14. Middle East & Africa Hepatitis Therapeutics Market Analysis and Forecast
14.1.Introduction
14.2.Market Value Forecast, by Disease Type, 2016–2026
14.2.1. Hepatitis A
14.2.2. Hepatitis B
14.2.3. Hepatitis C
14.2.4. Others
14.3.Market Value Forecast, by Drug Class, 2016–2026
14.3.1. Nucleotide Analog Reverse Transcriptase Inhibitor
14.3.2. NS5A Inhibitor
14.3.3. Multi-class Combination
14.3.4. Nucleotide Analog NS5B Polymerase Inhibitor
14.3.5. Interferon & Ribavirin
14.3.6. Others
14.4.Market Value Forecast, by Distribution Channel, 2016–2026
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5.Market Value Forecast, by Country, 2016–2026
14.5.1. GCC Countries
14.5.2. South Africa
14.5.5. Rest of Middle East & Africa
14.6.Market Attractiveness, Analysis
14.6.1. By Disease Type
14.6.2. By Drug Class
14.6.3. By Distribution Channel
14.6.4. By Country
15. Competition Landscape
15.1.Market Share Analysis, by Company (2017)
15.2. Company Profiles
15.2.1. Gilead Sciences, Inc.
15.2.2. F. Hoffmann-La Roche, Ltd.
15.2.3. Bristol Myers Squibb
15.2.4. Merck & Co., Inc.
15.2.5. AbbVie Inc.
15.2.6. NATCO Pharma Limited
15.2.7. Zydus Cadila
15.2.8. Hetero Healthcare Limited
15.2.9. LAURUS Labs
15.2.10. Cipla, Inc.